ClinicalTrials.gg
CompletedNCT01694277Updated Dec 8, 2020

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

A Phase 3 interventional study of Masitinib and Sunitinib in Gastrointestinal Stromal Tumors, sponsored by AB Science. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Gastrointestinal Stromal Tumors with a site in France — 8 open to participants now, 15 under way, 5 of them phase 3. Gastrointestinal Stromal Tumors · France.

Enrollment
11th of 45
258 · median 94
Started
2012
with 2 others
Phase 3
15 of 48
3 open now
Registered
21st of 48
by date
Lead sponsor
2 of 48
AB Science

Among the 48 studies in Gastrointestinal Stromal Tumors with a site in France, this one is the 11th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2012, is one of 15 in phase 3, and was the 21st registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

8 of the 48 studies in Gastrointestinal Stromal Tumors with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Gastrointestinal Stromal Tumors with a site in France, or all of them as a file.
02

Study summary

The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in the treatment of patients with gastro-intestinal stromal tumor (GIST) after progression with imatinib.

Read the detailed description

Masitinib is a selective tyrosine kinase inhibitor with potent activity against wild-type c-Kit, the juxta membrane domain of c-Kit, and PDGFR. Masitinib is also thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment. The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day with respect to sunitinib at 50 mg/day in the treatment of imatinib-resistant gastro-intestinal stromal tumor (GIST).

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • Gastrointestinal Stromal Tumour
  • GIST
  • non-resectable
  • metastatic
  • second line treatment
  • resistance to imatinib
  • tyrosine kinase inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria include:

  • Patient with histological proven GIST or non-operable locally advanced GIST
  • Patient with c-Kit (CD117) positive tumor detected immuno-histochemically
  • Patient after at least one progression with imatinib at a dose up to 800mg. Progression is defined as a 1.1 and/or CHOI disease progression while receiving imatinib treatment.

Main exclusion criteria include:

  • Patient treated for a cancer other than GIST within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ
  • Patient with active central nervous system (CNS) metastasis or with history of
  • Pregnant, or nursing female patient
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Masitinib

    Participants receive masitinib (12 mg/kg/day), given orally twice daily.

    Drug: Masitinib

  • Active comparator
    Sunitinib

    Participants receive sunitinib, given at 50 mg/day for 4 consecutive weeks out of 6 weeks, orally

    Drug: Sunitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as time in months from the randomization date to the date of death due to any cause. If a patient is not known to have died, then OS will be censored at the date of last known date patient alive.

    Time frame: From day of randomization to death, assessed for a maximum of 60 months

Secondary outcomes

  1. Survival rate

    Survival rate is defined as the number of patients alive divided by the number of patients in the population of analysis. Assessed at week-8, -16, -24, and every 12 weeks thereafter.

    Time frame: Every 12 weeks until study completion, assessed for a maximum of 60 months

  2. Progression Free Survival (PFS)

    Progression Free Survival is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Disease progression will be assessed by the investigator on CT scan according to RECIST 1.1 criteria and/or CHOI criteria.

    Time frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months

07

Study locations

5 sites
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Institut Bergonié
    Bordeaux, 33000, France
  • Hôpital l'Archet 2- Service de Cancérologie Digestive
    Nice, 06202, France
  • Istituto per la Ricerca e la Cura del Cancro (IRCC)
    Candiolo, 10060, Italy
  • Erasmus University Medical Center
    Rotterdam, 3015 GD, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Dec 2020 and a completion of Dec 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2012
First posted
Sep 27, 2012
Start
Apr 2012
Primary completionActual
Dec 2020
CompletionActual
Dec 2020
Results delay requested
Dec 7, 2020
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01694277
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Sep 27, 2012
Start date
Apr 2012
Primary completion
Dec 2020
Completion
Dec 2020
Last update
Dec 8, 2020

Study contacts

Axel Le Cesne, M.D., Ph.D
principal investigator · Institute Gustave Roussy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion